[Form 4] Eli Lilly & Co. Insider Trading Activity
J. Erik Fyrwald, a director of Eli Lilly & Co. (LLY), reported acquiring 74,591.985 shares of the company's common stock on 08/18/2025 at a per-share price of $698.05. The filing states these shares were elected to be deferred in lieu of cash compensation under the Lilly Directors' Deferral Plan and will be settled in shares following the reporting person鈥檚 separation from service. The transaction is reported as an acquisition of non-derivative common stock via Code A (acquisition).
J. Erik Fyrwald, consigliere di Eli Lilly & Co. (LLY), ha dichiarato di aver acquisito 74.591,985 azioni ordinarie della societ脿 il 18/08/2025 al prezzo unitario di $698,05. La comunicazione specifica che queste azioni sono state scelte come differimento in sostituzione della retribuzione in contanti ai sensi del Lilly Directors' Deferral Plan e saranno liquidate in azioni al momento della cessazione dell'incarico della persona che effettua la segnalazione. L'operazione 猫 riportata come acquisizione di azioni ordinarie non-derivative con codice A (acquisizione).
J. Erik Fyrwald, director de Eli Lilly & Co. (LLY), inform贸 haber adquirido 74.591,985 acciones ordinarias de la compa帽铆a el 18/08/2025 a un precio por acci贸n de $698.05. La presentaci贸n indica que estas acciones fueron elegidas para diferirse en lugar de la compensaci贸n en efectivo conforme al Lilly Directors' Deferral Plan y se liquidar谩n en acciones tras la separaci贸n del informante del servicio. La transacci贸n se registra como una adquisici贸n de acciones ordinarias no derivadas bajo el C贸digo A (adquisici贸n).
J. Erik Fyrwald, Eli Lilly & Co. (LLY) 鞚挫偓, 電� 2025-08-18鞐� 須岇偓 氤错喌欤� 74,591.985欤茧ゼ 欤茧嫻 $698.05鞐� 旆摑頄堧嫟瓿� 氤搓碃頄堨姷雼堧嫟. 鞁犼碃靹滌棎電� 鞚� 欤检嫕霌れ澊 順勱笀 氤挫垬 雽�鞁� Lilly Directors' Deferral Plan鞐� 霐半澕 鞚挫棸霅橁赴搿� 靹犿儩霅橃棃鞙茧┌, 鞁犼碃鞚胳潣 攴茧 膦呺 鞁滌爯鞐� 欤检嫕鞙茧 鞝曥偘霅� 瓴冹澊霛缄碃 氇呾嫓霅橃柎 鞛堨姷雼堧嫟. 頃措嫻 瓯半灅電� 旖旊摐 A(旆摑)鞐� 霐半ジ 牍勴寣靸� 氤错喌欤� 旆摑鞙茧 氤搓碃霅╇媹雼�.
J. Erik Fyrwald, administrateur d'Eli Lilly & Co. (LLY), a d茅clar茅 avoir acquis 74鈥�591,985 actions ordinaires de la soci茅t茅 le 18/08/2025698,05 $. Le d茅p么t indique que ces actions ont 茅t茅 choisies pour 锚tre diff茅r茅es en lieu et place d'une r茅mun茅ration en esp猫ces en vertu du Lilly Directors' Deferral Plan et seront r茅gl茅es en actions lors de la cessation de fonctions de la personne d茅clarant. La transaction est signal茅e comme une acquisition d'actions ordinaires non d茅riv茅es via le code A (acquisition).
J. Erik Fyrwald, ein Direktor von Eli Lilly & Co. (LLY), meldete den Erwerb von 74.591,985 Stammaktien des Unternehmens am 18.08.2025 zu einem St眉ckpreis von $698,05. In der Meldung hei脽t es, dass diese Aktien anstelle einer Barverg眉tung gem盲脽 dem Lilly Directors' Deferral Plan zur Aufschiebung gew盲hlt wurden und bei Ausscheiden der meldenden Person in Aktien ausgezahlt werden. Die Transaktion wird als Erwerb von nicht-derivativen Stammaktien unter Code A (Erwerb) gemeldet.
- Director converted compensation into equity, which aligns the reporting person's interests with long-term shareholders
- Clear numeric disclosure of shares (74,591.985) and per-share value ($698.05) enables investor assessment of insider exposure
- No material negative events disclosed in this Form 4; transaction reflects a compensation deferral rather than a sale
Insights
TL;DR: Director deferred compensation into company stock, aligning long-term interests with shareholders.
The reporting indicates a director elected to convert director cash compensation into equity units under the company's deferral plan rather than receiving cash. These units represent a meaningful number of shares (74,591.985) and will convert to common stock upon separation from service, which preserves retention incentives and enhances alignment with shareholder outcomes. The disclosure is routine for executive/director compensation elections and contains no indications of stock sales or hedging.
TL;DR: Large notional equity accrual disclosed; transaction is compensatory, not an open-market purchase.
The Form 4 reports a substantial accumulation of common stock units acquired through a director deferral plan at a reported per-share value of $698.05. Because the units are deferred compensation to be settled in shares after separation, this is an internal compensation election rather than an immediate market purchase, limiting near-term market liquidity impact. The filing includes clear numeric disclosure of shares and per-share price, allowing investors to quantify the director's equity exposure.
J. Erik Fyrwald, consigliere di Eli Lilly & Co. (LLY), ha dichiarato di aver acquisito 74.591,985 azioni ordinarie della societ脿 il 18/08/2025 al prezzo unitario di $698,05. La comunicazione specifica che queste azioni sono state scelte come differimento in sostituzione della retribuzione in contanti ai sensi del Lilly Directors' Deferral Plan e saranno liquidate in azioni al momento della cessazione dell'incarico della persona che effettua la segnalazione. L'operazione 猫 riportata come acquisizione di azioni ordinarie non-derivative con codice A (acquisizione).
J. Erik Fyrwald, director de Eli Lilly & Co. (LLY), inform贸 haber adquirido 74.591,985 acciones ordinarias de la compa帽铆a el 18/08/2025 a un precio por acci贸n de $698.05. La presentaci贸n indica que estas acciones fueron elegidas para diferirse en lugar de la compensaci贸n en efectivo conforme al Lilly Directors' Deferral Plan y se liquidar谩n en acciones tras la separaci贸n del informante del servicio. La transacci贸n se registra como una adquisici贸n de acciones ordinarias no derivadas bajo el C贸digo A (adquisici贸n).
J. Erik Fyrwald, Eli Lilly & Co. (LLY) 鞚挫偓, 電� 2025-08-18鞐� 須岇偓 氤错喌欤� 74,591.985欤茧ゼ 欤茧嫻 $698.05鞐� 旆摑頄堧嫟瓿� 氤搓碃頄堨姷雼堧嫟. 鞁犼碃靹滌棎電� 鞚� 欤检嫕霌れ澊 順勱笀 氤挫垬 雽�鞁� Lilly Directors' Deferral Plan鞐� 霐半澕 鞚挫棸霅橁赴搿� 靹犿儩霅橃棃鞙茧┌, 鞁犼碃鞚胳潣 攴茧 膦呺 鞁滌爯鞐� 欤检嫕鞙茧 鞝曥偘霅� 瓴冹澊霛缄碃 氇呾嫓霅橃柎 鞛堨姷雼堧嫟. 頃措嫻 瓯半灅電� 旖旊摐 A(旆摑)鞐� 霐半ジ 牍勴寣靸� 氤错喌欤� 旆摑鞙茧 氤搓碃霅╇媹雼�.
J. Erik Fyrwald, administrateur d'Eli Lilly & Co. (LLY), a d茅clar茅 avoir acquis 74鈥�591,985 actions ordinaires de la soci茅t茅 le 18/08/2025698,05 $. Le d茅p么t indique que ces actions ont 茅t茅 choisies pour 锚tre diff茅r茅es en lieu et place d'une r茅mun茅ration en esp猫ces en vertu du Lilly Directors' Deferral Plan et seront r茅gl茅es en actions lors de la cessation de fonctions de la personne d茅clarant. La transaction est signal茅e comme une acquisition d'actions ordinaires non d茅riv茅es via le code A (acquisition).
J. Erik Fyrwald, ein Direktor von Eli Lilly & Co. (LLY), meldete den Erwerb von 74.591,985 Stammaktien des Unternehmens am 18.08.2025 zu einem St眉ckpreis von $698,05. In der Meldung hei脽t es, dass diese Aktien anstelle einer Barverg眉tung gem盲脽 dem Lilly Directors' Deferral Plan zur Aufschiebung gew盲hlt wurden und bei Ausscheiden der meldenden Person in Aktien ausgezahlt werden. Die Transaktion wird als Erwerb von nicht-derivativen Stammaktien unter Code A (Erwerb) gemeldet.
FAQ
What transaction did Eli Lilly director J. Erik Fyrwald report on Form 4?
Was the reported transaction a market purchase or part of a deferral plan?
Does the Form 4 show any sales or derivative transactions by the reporting person?
How many shares will the reporting person beneficially own after the transaction?
Who signed the Form 4 on behalf of the reporting person?
